Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theratechnologies Inc (NQ: THTX )

1.260 -0.060 (-4.55%)
Streaming Delayed Price Updated: 11:41 AM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18,418
Open 1.350
Bid (Size) 1.260 (6)
Ask (Size) 1.350 (6)
Prev. Close 1.320
Today's Range 1.260 - 1.350
52wk Range 0.8800 - 3.920
Shares Outstanding 77,013,411
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports on its Annual Meeting of Shareholders
From Theratechnologies
Via GlobeNewswire

Performance

YTD
-25.44%
-25.44%
1 Month
+0.80%
+0.80%
3 Month
+2.44%
+2.44%
6 Month
-16.56%
-16.56%
1 Year
-66.18%
-66.18%

More News

Read More
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
From Theratechnologies
Via GlobeNewswire
Earnings Scheduled For February 21, 2024
Via Benzinga
Theratechnologies Earnings Preview
Via Benzinga
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Theratechnologies
Via GlobeNewswire
THTX Stock Earnings: Theratechnologies Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
From Theratechnologies
Via GlobeNewswire
Earnings Scheduled For April 10, 2024
Via Benzinga
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
From Theratechnologies
Via GlobeNewswire
Theratechnologies Appoints Elina Tea to its Board of Directors
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Update on its Preclinical Oncology Research Program
From Theratechnologies
Via GlobeNewswire
Theratechnologies Appoints Jordan Zwick to its Board of Directors
From Theratechnologies
Via GlobeNewswire
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
From Theratechnologies
Via GlobeNewswire
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
From Theratechnologies
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.